• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Oncolin Therapeutics, Inc. - Product Pipeline Review - Q4 2010 Product Image

Oncolin Therapeutics, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 21 pages
  • GlobalData

Oncolin Therapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Oncolin Therapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oncolin Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncolin Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Oncolin Therapeutics, Inc. Snapshot
Oncolin Therapeutics, Inc. Overview
Key Information
Key Facts
Oncolin Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Oncolin Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Oncolin Therapeutics, Inc. – Pipeline Products Glance
Oncolin Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Oncolin Therapeutics, Inc. – Drug Profiles
Antimetabolite Inhibitor Of Glycolysis
Product Description
Mechanism of Action
R&D Progress
ONC-127
Product Description
Mechanism of Action
R&D Progress
Inhibitors Of Glycolytic Enzymes
Product Description
Mechanism of Action
R&D Progress
Novel Microtubule Inhibitor
Product Description
Mechanism of Action
R&D Progress
Thermally Activated Chemotherapy
Product Description
Mechanism of Action
R&D Progress
Oncolin Therapeutics, Inc. – Pipeline Analysis
Oncolin Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Oncolin Therapeutics, Inc. Pipeline Products By Target
Oncolin Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 16, 2008: Oncolin Therapeutics Announces Its New 'Super Cell Blocker', ONC-127, Has Shown Effectiveness In Treating Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS